Literature DB >> 22977534

Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer.

Meng Wang1, Gong-Yan Chen, Hong-Tao Song, Xuan Hong, Zhao-Yang Yang, Guang-Jie Sui.   

Abstract

C-X-C chemokine receptor type 4 (CXCR4) plays an important role in determining the metastatic potential of non-small cell lung cancer. In order to elucidate the effect and mechanism of CXCR4 in tumor angiogenesis we evaluated the clinical significance of CXCR4, phosphorylated signal transducer and activator of transcription 3 (P-STAT3), and vascular endothelial growth factor (VEGF) expression in patients with completely resected non-small cell lung cancer (NSCLC). A total of 208 cases of resected NSCLC were collected, and expression of CXCR4, P-STAT3 and VEGF-A in tumor tissue was investigated using immunohistochemistry (IHC). We reviewed the patient clinical records to determine the association of the expression of these proteins with the clinical course of the disease. Expression of CXCR4, P-STAT3 and VEGF-A was detected in 56.3, 46.2 and 51.9% of the samples, respectively. We observed co-expression between CXCR4, P-STAT3 and VEGF-A. Using multivariate analysis, the expression levels of CXCR4 and VEGF-A were identified as independent prognostic factors that affected overall survival. In conclusion, the results of this study suggest that CXCR4, P-STAT3 and VEGF-A expression may play a role in tumor progression and angiogenesis of NSCLC. However, further studies are needed to uncover the detailed mechanism that underlies the role of these proteins in NSCLC.

Entities:  

Year:  2011        PMID: 22977534      PMCID: PMC3440730          DOI: 10.3892/etm.2011.235

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  30 in total

1.  Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression.

Authors:  Yu-Ping Jiang; Xiao-Hua Wu; Bin Shi; Wen-Xin Wu; Gui-Ran Yin
Journal:  Gynecol Oncol       Date:  2006-05-02       Impact factor: 5.482

2.  Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten.

Authors:  Isaia Barbieri; Sara Pensa; Tania Pannellini; Elena Quaglino; Diego Maritano; Marco Demaria; Alessandra Voster; James Turkson; Federica Cavallo; Christine J Watson; Paolo Provero; Piero Musiani; Valeria Poli
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

3.  Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.

Authors:  Joseph Kim; Hiroya Takeuchi; Stella T Lam; Roderick R Turner; He-Jing Wang; Christine Kuo; Leland Foshag; Anton J Bilchik; Dave S B Hoon
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

4.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.

Authors:  R Garcia; T L Bowman; G Niu; H Yu; S Minton; C A Muro-Cacho; C E Cox; R Falcone; R Fairclough; S Parsons; A Laudano; A Gazit; A Levitzki; A Kraker; R Jove
Journal:  Oncogene       Date:  2001-05-03       Impact factor: 9.867

5.  Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer.

Authors:  Carl C Schimanski; Stefan Schwald; Nektaria Simiantonaki; Caren Jayasinghe; Ursula Gönner; Vanessa Wilsberg; Theodor Junginger; Martin R Berger; Peter R Galle; Markus Moehler
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

6.  Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells.

Authors:  Sandra Cascio; Rita Ferla; Aleco D'Andrea; Aldo Gerbino; Viviana Bazan; Eva Surmacz; Antonio Russo
Journal:  J Cell Physiol       Date:  2009-10       Impact factor: 6.384

7.  Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis.

Authors:  Il-Kang Na; Carmen Scheibenbogen; Christine Adam; Andrea Stroux; Pirus Ghadjar; Eckhard Thiel; Ulrich Keilholz; Sarah Ellen Coupland
Journal:  Hum Pathol       Date:  2008-08-12       Impact factor: 3.466

8.  Vascular endothelial growth factor and endoglin expression in colorectal cancer.

Authors:  Konstantinos Dassoulas; Maria Gazouli; George Theodoropoulos; Zoi Christoni; Spyros Rizos; Adamantia Zisi-Serbetzoglou; Chrissa Glava; Theodoros Karantanos; Christos Klonaris; Petros Karakitsos
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-05       Impact factor: 4.553

9.  Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma.

Authors:  Yoshinao Oda; Naomi Tateishi; Hiroshi Matono; Suguru Matsuura; Hidetaka Yamamaoto; Sadafumi Tamiya; Ryohei Yokoyama; Shuichi Matsuda; Yukihide Iwamoto; Masazumi Tsuneyoshi
Journal:  Int J Cancer       Date:  2009-04-15       Impact factor: 7.396

10.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

View more
  20 in total

Review 1.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

2.  Chemokine receptor CXCR4 expression and lung cancer prognosis: a meta-analysis.

Authors:  Jin-Xiao Liang; Wei Gao; Yong Liang; Xin-Ming Zhou
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome.

Authors:  Kathleen C Light; Neeraj Agarwal; Eli Iacob; Andrea T White; Anita Y Kinney; Timothy A VanHaitsma; Hannah Aizad; Ronald W Hughen; Lucinda Bateman; Alan R Light
Journal:  Psychoneuroendocrinology       Date:  2013-09-06       Impact factor: 4.905

Review 4.  Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.

Authors:  Weiqiang Zhou; Shanchun Guo; Mingli Liu; Matthew E Burow; Guangdi Wang
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

5.  EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.

Authors:  Timothy D Clay; Prudence A Russell; Hongdo Do; Vijaya Sundararajan; Matthew Conron; Gavin M Wright; Benjamin Solomon; Alexander Dobrovic; Sue-Anne McLachlan; Melissa M Moore
Journal:  Med Oncol       Date:  2017-09-06       Impact factor: 3.064

6.  The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.

Authors:  Liping Qiu; Yuanyuan Xu; Hui Xu; Biyun Yu
Journal:  BMC Cancer       Date:  2022-06-21       Impact factor: 4.638

7.  Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.

Authors:  Claudia Stumpf; Daniel Kaemmerer; Elisa Neubauer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

8.  CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer.

Authors:  Hai-bo Shen; Zheng-qin Gu; Kang Jian; Juan Qi
Journal:  Tumour Biol       Date:  2013-03-23

9.  Expression of CXCR4 and non-small cell lung cancer prognosis: a meta-analysis.

Authors:  Kun Liu; Cihang Bao; Nengliang Yao; Chao Miao; John Varlotto; Qiang Sun; Xiaojie Sun
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 10.  CXCR4 over-expression and survival in cancer: a system review and meta-analysis.

Authors:  Hongli Zhao; Liyuan Guo; Hong Zhao; Jiaxin Zhao; Hao Weng; Bin Zhao
Journal:  Oncotarget       Date:  2015-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.